Cytotoxic T lymphocytes (CTLs) specific for an HLA-A2-presented peptide epitope of the Wilms tumor antigen-1 (WT1) can selectively kill immature human leukemia progenitor and stem cells in vitro. In this study we have used retroviral gene transfer to introduce a WT1-specific T-cell receptor (TCR) into T lymphocytes obtained from patients with leukemia and from healthy donors. TCR-transduced T cells kill leukemia cells in vitro and display WT1-specific cytokine production. Intravenous injection of TCR-transduced T cells into nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice harboring human leukemia cells resulted in leukemia elimination, whereas transfer of control T cells transduced with an irrelevant TCR was ineffective. The data suggest that adoptive immunotherapy with WT1-TCR gene-modified patient T cells should be considered for the treatment of leukemia. © 2005 by The American Society of Hematology.
CITATION STYLE
Xue, S. A., Gao, L., Hart, D., Gillmore, R., Qasim, W., Thrasher, A., … Stauss, H. (2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood, 106(9), 3062–3067. https://doi.org/10.1182/blood-2005-01-0146
Mendeley helps you to discover research relevant for your work.